Oral mucositis (severe) · breast cancer patients undergoing chemotherapy
Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of TAS2R43 (chr12p13.2) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted expression of TAS2R43 was significantly associated with ECC in the TWAS (p = 8.78e-8); genetic association, ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of SMIM10L1 (chr12p13.2) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted expression of SMIM10L1 was significantly associated with ECC in the TWAS (p = 1.70e-7); genetic association, ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of LACC1 (chr13q14.11) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted LACC1 expression reached the TWAS threshold for ECC (p = 3.98e-5) but was flagged as a possible false positive (LD misspecification) and not further considered; ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of NRAD1 (LINC00284) (chr13q14.11) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted NRAD1 (LINC00284) expression reached the TWAS threshold for ECC (p = 1.69e-6) but was flagged as a possible false positive (LD misspecification) and not further considered; ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of TAS2R31 (chr12p13.2) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted expression of TAS2R31 was suggestively associated with ECC in the TWAS (p = 1.04e-5); genetic association, ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of TAS2R14 (chr12p13.2) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted expression of TAS2R14 was significantly associated with ECC in the TWAS (p = 1.06e-6); genetic association, ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of IGSF5 (chr21q22.2) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted IGSF5 expression reached the TWAS threshold for ECC (p = 7.22e-5) but was flagged as a possible false positive (LD misspecification) and not further considered; ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of LINC02905 (C8orf49) (chr8p23.1) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted LINC02905 (C8orf49) expression reached the TWAS threshold for ECC (p = 1.82e-8) but was flagged as a possible false positive (LD misspecification) and not further considered; ungraded.
1 finding from 1 review
Early childhood caries (ECC) - association with genetically predicted expression of CDH17 (chr8q22.1) · Children up to age 5-6 years (European / European non-Hispanic ancestry); 843 ECC-affected vs 2124 unaffected across 5 cohorts (N=2974)
Genetically predicted expression of CDH17 was significantly associated with ECC in the TWAS (p = 3.32e-8); genetic association, ungraded.
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Reduction in target/mean lesion size · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in reduction in target/mean lesion size compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Patient preference for active sprays vs placebo nearly attained significance (Chi2 7.259, df=3; P = 0.064); 15/43 participants expressed no desire to continue any spray after the trial.
1 study · 43 participants
GRADE not reported
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to GM-CSF typically bone pain, nausea, fever and headache; not reported as serious; reporting poor and inconsistent (SoF comments cell, not GRADE-rated)
8 studies
GRADE not reported
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (severe) compared with placebo or no treatment (low certainty).
3 findings from 1 review
RR 0.74 [0.33, 1.67]
3 studies · 235 participants
Low
RR 0.59 [0.05, 7.11]
2 studies · 65 participants
Very low
RR 0.31 [0.01, 7.09]
1 study · 29 participants
Very low
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Oral pain · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral pain (mean pain score, 0 to 10 scale) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review